期刊
SEMINARS IN ARTHRITIS AND RHEUMATISM
卷 58, 期 -, 页码 -出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2022.152129
关键词
Autoimmune rheumatic diseases; SARS-COV-2; Delta and Omicron Variants
类别
This study aimed to describe the impact of COVID-19 on Autoimmune Rheumatic Disease (ARD) patients and found that the Omicron variant had milder clinical impacts compared to the Delta variant. ARD patients infected with the Omicron variant had a lower risk of COVID-19-related hospitalization and death compared to those infected with the Delta variant.
Objective: The Omicron variant of the coronavirus SARS-CoV-2 (COVID-19) had milder clinical impacts than prior variants. This study aimed to describe the impact of COVID-19 on Autoimmune Rheumatic Disease (ARD) patients during the Delta and Omicron variants waves. Methods: We used data from Clalit Health Services (CHS), the largest health service in Israel. ARD patients diagnosed with COVID-19 between July 1, 2021, to December 1, 2021, were included in the Delta group. Patients diagnosed between December 2, 2021, to March 31, 2022, were included in the Omicron group based on the predominance of COVID-19 in Israel. The study outcomes were COVID-19-related hospitalization or death. Results: The final study cohort included 8443 actively treated ARD patients diagnosed with COVID-19. 1204 patients were positive during the predefined Delta variant period, and 7249 were positive during the predefined Omicron variant period). Compared to the Delta group, the Omicron group showed a lower rate of COVID-19related hospitalization (3.9% vs. 1.3% for the Delta Vs. Omicron accordingly, p<0.001) and COVID-19-related death (3.2% vs. 1.1% for the Delta Vs. Omicron accordingly, p<0.001). After applying multivariable regression models, the Omicron group showed a lower risk for COVID-19-related hospitalization (Relative risk 0.4, 95% CI 0.27-0.59) and COVID-19-related mortality (RR 0.48, 95% CI 0.31-0.75). Conclusion: ARD patients infected with the COVID-19 Omicron variant had a lower risk of developing COVID-19related adverse outcomes compared to the Delta variant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
Article
Rheumatology
Systematic calibration reduces sources of variability for the preliminary OMERACT juvenile idiopathic arthritis MRI- sacroiliac joint score (OMERACT JAMRIS-SIJ)
Walter P. Maksymowych, Nele Herregods, Nisha Varma, Arthur B. Meyers, Jennifer Stimec, Andrea S. Doria, Nikolay Tzaribachev, Tarimobo M. Otobo, Marion A. van Rossum, Joel Paschke, Stephanie Wichuk, Robert G. Lambert
Summary: This study aimed to investigate whether systematic calibration improves the scoring proficiency of JAMRIS-SIJ and whether contrast-enhancement enhances its performance. The results showed that calibrated readers achieved greater reliability in scoring specific inflammatory and structural lesions. Sensitivity and reliability for scoring inflammatory lesions were higher on fluid-sensitive sequences compared to contrast-enhanced sequences. Therefore, systematic calibration should be implemented before using JAMRIS-SIJ in clinical trials, and it is unlikely that contrast-enhanced MRI will improve the performance of this method.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2024)
Article
Rheumatology
Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis
L. van Ouwerkerk, S. A. Bergstra, T. D. Maarseveen, T. W. J. Huizinga, R. Knevel, C. F. Allaart
Summary: This study evaluated whether the initial use of glucocorticoid (GC) bridging in RA patients leads to a higher probability of long-term GC and bDMARD use. The results showed that patients who initially started GC had a higher risk of later GC use, but the risk of bDMARD use was not significantly increased.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2024)
Article
Rheumatology
Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review
ShuangHua Liu, YiMei Tan, WeiDong Huang, HongSheng Luo, BingCheng Pan, Shuan Wu
Summary: This study assessed the cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis. The results showed that in women with primary osteoporosis, zoledronic acid may increase the risk of atrial fibrillation and arrhythmias, but the cardiovascular risk in men with osteoporosis is uncertain.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2024)
分享论文
